Lucid Diagnostics: Strong Growth Potential Justifies Buy Rating
Kyle Mikson CFA, an analyst from Canaccord Genuity, maintained the Buy rating on Lucid Diagnostics (LUCD – Research Report). The ...
bovnews1d
10X Genomics Inc (TXG) Stock: More Resilient Than It Appears
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.28% ...
News Medical1d
Sphere Fluidics strengthens global commercial teams and establishes direct sales and support channel in North America
Sphere Fluidics, a leading provider of innovative droplet-based microfluidics solutions for functional profiling of single ...
10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Axxcess Wealth Management LLC
Axxcess Wealth Management LLC boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 38.5% during ...
Le Lézard2d
Genomics Market to Hit USD 66.85 Billion by 2029 with 9.4% CAGR | MarketsandMarketstm
The global genomics market is expected to reach USD 66.85 billion in 2029 from USD 42.64 billion in 2024, at a CAGR of 9.4% ...
Morgan Stanley Remains a Buy on Guardant Health (GH)
In a report released today, Tejas Savant from Morgan Stanley maintained a Buy rating on Guardant Health (GH – Research Report), with a ...
bovnews5d
Uncover the Reason: Why 10X Genomics Inc (TXG) Stock Is Trading 13.41% Above Its 52-Week Low?
Leerink Partners has recently initiated 10X Genomics Inc (TXG) stock to Outperform rating, as announced on September 3, 2024, according to Finviz. Earlier, on July 22, 2024, Jefferies had raised the ...